| Literature DB >> 23658847 |
Dorothy Yeboah-Manu1, Grace S Kpeli, Marie-Thérèse Ruf, Kobina Asan-Ampah, Kwabena Quenin-Fosu, Evelyn Owusu-Mireku, Albert Paintsil, Isaac Lamptey, Benjamin Anku, Cynthia Kwakye-Maclean, Mercy Newman, Gerd Pluschke.
Abstract
Buruli ulcer (BU), caused by Mycobacterium ulcerans is a chronic necrotizing skin disease. It usually starts with a subcutaneous nodule or plaque containing large clusters of extracellular acid-fast bacilli. Surrounding tissue is destroyed by the cytotoxic macrolide toxin mycolactone produced by microcolonies of M. ulcerans. Skin covering the destroyed subcutaneous fat and soft tissue may eventually break down leading to the formation of large ulcers that progress, if untreated, over months and years. Here we have analyzed the bacterial flora of BU lesions of three different groups of patients before, during and after daily treatment with streptomycin and rifampicin for eight weeks (SR8) and determined drug resistance of the bacteria isolated from the lesions. Before SR8 treatment, more than 60% of the examined BU lesions were infected with other bacteria, with Staphylococcus aureus and Pseudomonas aeruginosa being the most prominent ones. During treatment, 65% of all lesions were still infected, mainly with P. aeruginosa. After completion of SR8 treatment, still more than 75% of lesions clinically suspected to be infected were microbiologically confirmed as infected, mainly with P. aeruginosa or Proteus miriabilis. Drug susceptibility tests revealed especially for S. aureus a high frequency of resistance to the first line drugs used in Ghana. Our results show that secondary infection of BU lesions is common. This could lead to delayed healing and should therefore be further investigated.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23658847 PMCID: PMC3642065 DOI: 10.1371/journal.pntd.0002191
Source DB: PubMed Journal: PLoS Negl Trop Dis ISSN: 1935-2727
Figure 1Histopathological analysis of tissue excised before start of SR8 treatment.
Histological sections were stained with Ziehl-Neelsen (acid fast bacteria) and methylene blue (DNA, secondary infection). A: Overview over excised tissue specimen revealing infection at the lower end of the specimen (box), as well as BU characteristic histopathological features, including fat cell ghosts, necrosis and epidermal hyperplasia. B/C: higher magnification revealing the presence of cocci. D: clinical presentation of the lesion on the belly.
Spectrum of bacterial species isolated from BU lesions before, during or after SR8 treatment.
| Time of sampling | Clean wounds | Contaminated wounds | Infected wounds | Spectrum of bacteria isolates from infected cases n (%) |
| Before SR8 Treatment (n = 53) | 3 (6%) | 17 (32%) | 33 (62%) | 9 (22%) |
| 7 (17%) | ||||
| 6 (15%) | ||||
| 3 (7%) Coagulase negative Staph. | ||||
| 3 (7%) | ||||
| 2 (5%) | ||||
| 2 (5%) | ||||
| 2 (5%) | ||||
| 1 (2%) | ||||
| 1 (2%) | ||||
| 1 (2%) | ||||
| 1 (2%) | ||||
| 1 (2%) | ||||
| 1 (2%) | ||||
| 1 (2%) | ||||
| During SR8 Treatment (n = 20) | 0 (0%) | 7 (35%) | 13 (65%) | 6 (38%) |
| 2 (13%) | ||||
| 1 (6%) | ||||
| 1 (6%) Coagulase negative Staph. | ||||
| 1 (6%) | ||||
| 1 (6%) | ||||
| 1 (6%) | ||||
| 1 (6%) | ||||
| 1 (6%) | ||||
| 1 (6%) | ||||
| After SR8 Treatment (n = 31; clinically diagnosed for secondary infection) | 0 (0%) | 7 (23%) | 24 (77%) | 8 (32%) |
| 5 (20%) | ||||
| 3 (12%) | ||||
| 2 (8%) | ||||
| 2 (8%) | ||||
| 2 (8%) | ||||
| 1 (4%) Coagulase negative Staph. | ||||
| 1 (4%) | ||||
| 1 (4%) |
Presentation of wounds that were clinically infected after SR8 compared to microbiology and histology findings.
| BU Case | Clinical Presentation | Microbiological category | Species | Histopathology | Location (in the tissue) | ||||||||
| Odor | Pain | Green discharge | Yellow discharge | Necrotic tissue | Bloody discharge | WHD | Edema | SGF | |||||
|
| Yes | Yes | No | Yes | Yes | No | Yes | No | Yes | Infected | Mixed growth | Rods/Cocci | Stratum corneum |
|
| Yes | Yes | No | Yes | Yes | No | Yes | No | Yes | Infected |
| None | |
|
| No | Yes | No | Yes | Yes | No | Yes | Yes | No | Infected |
| Rods | Stratum corneum |
|
| No | Yes | No | Yes | No | No | No | No | No | Infected | Mixed growth/ | Rods/Cocci | Stratum corneum |
|
| No | Yes | No | Yes | Yes | No | No | No | No | Infected |
| n/d | |
|
| Yes | Yes | No | Yes | Yes | No | Yes | No | No | Infected |
| n/d | |
|
| Yes | Yes | No | Yes | Yes | Yes | Yes | Yes | No | Infected |
| n/d | |
|
| No | Yes | No | Yes | Yes | No | No | No | No | Contaminated |
| None | |
|
| Yes | Yes | Yes | Yes | Yes | No | Yes | No | No | Infected |
| Rods | Ulcer surface |
|
| Yes | Yes | No | Yes | Yes | No | No | No | No | Infected | Proteus mirabilis | None | |
|
| Yes | Yes | No | Yes | Yes | No | Yes | Yes | No | Infected |
| n/d | |
|
| Yes | Yes | No | Yes | Yes | No | Yes | No | No | Infected |
| None | |
|
| No | Yes | No | Yes | Yes | No | Yes | No | No | Infected |
| n/d | |
|
| Yes | Yes | No | Yes | Yes | Yes | Yes | No | No | Infected |
| Rods/Cocci | Ulcer surface |
|
| Yes | Yes | No | Yes | Yes | No | Yes | No | No | Infected |
| Rods | Ulcer surface |
|
| Yes | Yes | Yes | Yes | Yes | No | Yes | No | No | Infected |
| Rods/Cocci | Stratum corneum (cocci), Dermis, Subcutis (rods) |
|
| No | Yes | No | Yes | Yes | No | No | No | Yes | Infected | Gram negative rods | Rods | Dermis, Subcutis |
|
| Yes | Yes | No | Yes | Yes | No | Yes | No | No | Infected |
| Rods/Cocci | Stratum corneum |
|
| No | Yes | No | Yes | Yes | No | No | No | Yes | Infected | Mixed growth | Rods/Cocci | Stratum corneum |
|
| Yes | Yes | No | Yes | Yes | Yes | No | No | No | Contaminated | Gram negative rods | None | |
|
| No | Yes | No | Yes | Yes | No | Yes | No | No | Contaminated |
| None | |
|
| No | Yes | No | Yes | Yes | No | No | No | No | Contaminated |
| n/d | |
|
| No | Yes | No | Yes | No | No | Yes | No | No | Contaminated | Coagulase negative | n/d | |
|
| Yes | Yes | Yes | Yes | Yes | No | Yes | Yes | Yes | Infected | Acinetobacter sp. | Rods/Cocci | Subcutis |
|
| Yes | Yes | No | Yes | Yes | No | Yes | No | No | Infected |
| Rods | Subcutis |
|
| No | Yes | No | Yes | No | No | No | No | Yes | Infected |
| None | |
|
| No | Yes | No | Yes | No | Yes | No | Yes | No | Contaminated |
| None | |
|
| No | Yes | No | Yes | No | No | No | No | No | Contaminated |
| n/d | |
We compared the clinical presentation to microbiological categorization based on quantification and histological findings. Lesions with a bacterial load less than 106 CFU/ml (or CFU/g) were categorized as contaminated, while lesions with bacterial loads above were considered as infected.
WHD = Wound healing delay.
SGF = Skin grafting failure.
n/d = not done.
Figure 2Histopathological analysis of tissue from two patients excised weeks after SR8 treatment respectively.
Histological sections were stained with Ziehl-Neelsen (acid fast bacteria) and methylene blue (DNA, secondary infection). A: clinical presentation of patient 9 presenting with a large lesion on the right foot. B: overview over excised tissue specimen (open ulcer surface) revealing the presence of an infection (blue band, box). C/D: higher magnification confirming the presence of densely packed rods. E: clinical presentation of patient 16 presenting with a large lesion covering the left leg. F: overview over excised tissue specimen revealing an epidermal hyperplasia as well as a strong edema. G/H: secondary infection with rods of the dermal and subcutaneous tissue.
Antibiotic susceptibility pattern of different bacterial species isolated from BU wounds.
| Pathogen | Drug Tested | Number Tested | Susceptible, n(%) | Int. Resistant, n(%) | Resistant n(%) |
|
| Gentamicin | 22 | 18(81.9) | 1(4.5) | 3(13.6) |
| Ceftriaxone | 13 | 3(23.1) | 7(53.8) | 3(23.1) | |
| Cefotaxime | 20 | 1(5.0) | 1(5.0) | 18(90) | |
| Ampicillin | 22 | 0(0) | 0(0) | 22(100) | |
| Tetracycline | 22 | 3(13.6) | 1(4.5) | 18(81.9) | |
| Cotrimoxazole | 22 | 3(13.6) | 2(0) | 17(77.3) | |
| Cefuroxime | 22 | 0(0) | 0(0) | 22(100) | |
| Chloramphenicol | 21 | 2(9.5) | 2(9.5) | 17(81) | |
|
| Tetracycline | 18 | 12(66.7) | 0(0) | 6(33.3) |
| Cotrimoxazole | 18 | 16(88.9) | 0(0) | 2(11.1) | |
| Erythromycin | 18 | 9(50) | 9(50) | 0(0) | |
| Ampicillin | 18 | 2(11.1) | 1(5.6) | 15(83.3) | |
| Flucloxacillin | 18 | 3(16.7) | 0(0) | 15(83.3) | |
| Cefuroxime | 18 | 9(50) | 1(5.6) | 8(44.4) | |
| Gentamicin | 18 | 15(83.3) | 0(0) | 3(16.7) | |
| Methicillin | 18 | 12(66.7) | 0(0) | 6(33.3) | |
| Vancomycin | 18 | 15(83.3) | 0(0) | 3(16.7) | |
| Penicillin | 18 | 0(0) | 0(0) | 18(100) | |
| Other gram positive | Tetracycline | 13 | 6(46.2) | 0(0) | 7(53.8) |
| Cotrimoxazole | 13 | 7(53.8) | 0(0) | 6(46.2) | |
| Erythromycin | 13 | 6(46.2) | 3(23.1) | 4(30.7) | |
| Ampicillin | 13 | 3(23.1) | 1(7.7) | 9(69.2) | |
| Flucloxacillin | 13 | 2(15.4) | 0(0) | 11(84.6) | |
| Cefuroxime | 13 | 6(46.2) | 0(0) | 7(53.8) | |
| Gentamicin | 13 | 11(84.6) | 0(0) | 2(15.3) | |
| Penicillin | 13 | 2(15.4) | 0(0) | 11(84.6) | |
| Other gram negatives | Gentamicin | 45 | 37(82.2) | 1(2.2) | 7(15.6) |
| Ceftriaxone | 17 | 10(58.8) | 2(11.8) | 5(29.4) | |
| Cefotaxime | 39 | 16(41.0) | 4(10.3) | 19(48.7) | |
| Ampicillin | 45 | 0(0) | 1(2.2) | 44(97.8) | |
| Tetracycline | 45 | 1(2.3) | 0(0) | 44(97.8) | |
| Cotrimoxazole | 45 | 7(15.6) | 0(0) | 38(84.4) | |
| Cefuroxime | 45 | 5(11.1) | 10(22.2) | 30(66.7) | |
| Chloramphenicol | 39 | 6(15.4) | 2(5.1) | 31(79.5) |
Microbiological analysis of recycled bandages.
| CASE | BACTERIAL LOAD (CFU/g) | ORGANISM ISOLATED | ANTIBIOTIC SUSCEPTIBILITY | ||
| SENSITIVE | INTERMEDIATE | RESISTANT | |||
| CASE 1 | 9.5×107 |
| CTX, TET, AMK, COT, GEN, CHL | AMP, CRX | |
| CASE 2 | 5.3×107 |
| COT, CRX, GEN | ERY | PEN, AMP, FLX, TET |
| CASE 3 | 5.5×104 |
| TET, COT, CRX, GEN | ERY | PEN, AMP, FLX |
| CASE 4 | 1.10×106 |
| |||
| CASE 5 | 3.2×108 |
| TET, COT, CRX, GEN | PEN, AMP, FLX, TET | |
| CASE 6 | 1.22×105 |
| |||
| CASE 7 | 1.67×106 |
| TET, AMK, GEN | CRX, CTX | AMP, COT, CHL |
| CASE 8 | 8.6×105 |
| GEN | PEN, AMP, FLX, ERY, TET, COT, CRX | |
|
| CTX, TET, COT, CHL | AMP, CRX, AMK,GEN | |||
| CASE 9 | 4.1×103 |
| TET, COT, CRX, GEN | PEN, AMP, FLX, ERY | |
| CASE 10 | 3.3×105 |
| GEN | CRX | PEN, AMP, FLX, ERY, TET, COT |
| CASE 11 | 3.1×103 |
| TET, GEN | CRX | PEN, AMP, FLX, ERY, COT |
| CASE 12 | 6.3×104 |
| TET, COT, CRX, GEN | ERY | PEN, AMP, FLX |
| CASE 13 | 1.65×105 |
| CTX, TET, COT, GEN, CHL | AMK | AMP, CRX |
| CASE 14A | 4.4×104 |
| TET, GEN | CRX | PEN, AMP, FLX, ERY, COT |
| CASE 14B | 5.3×103 |
| GEN | PEN, AMP, FLX, ERY, TET, COT, CRX | |
| CASE 15A | NEGLIGIBLE |
| GEN | ERY, CRX | PEN, AMP, FLX, TET, COT |
| CASE 15B | NEGLIGIBLE |
| |||
AMP = Ampicillin, CXM = Cefixime, CXC = Cloxacillin, COT = Cotrimoxazole, ERY = Erythromycin, GEN = Gentamicin, TET = Tetracycline, PEN = Penicillin, CRX = Cefuroxime, CHL = Chloramphenicol, CTR = Ceftriaxone, CTX = Cefotaxime.